BRCA2 and pachyonychia congenita: Nine percent (94/1081) of evaluable PC patients in the CGDB were HRDsig(+), and the HRDsig+ cohort encompassed a larger population than that defined by BRCA1/BRCA2/PALB2 mutation (9% vs. 6% of PC cases in the CGDB) (Fig. 3A).